Search results
Results from the WOW.Com Content Network
Peter Attia (born March 19, 1973) [1] is a Canadian-American author, physician, and researcher known for his work in longevity medicine. He is the author of Outlive: The Science and Art of Longevity .
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa).
Outlive: The Science and Art of Longevity is a non-fiction health and wellness book authored by Peter Attia, a physician specializing in longevity, and co-written with journalist Bill Gifford. [1] Published in March 2023, Outlive was listed on The New York Times Best Seller list in 2023 and 2024.
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
The procedure is to take the child's weight in pounds, divide by 150 lb, and multiply the fractional result by the adult dose to find the equivalent child dosage.For example, if an adult dose of medication calls for 30 mg and the child weighs 30 lb, divide the weight by 150 (30/150) to obtain 1/5 and multiply 1/5 times 30 mg to get 6 mg.
The mammalian target of rapamycin (mTOR), [5] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene. [6] [7] [8] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein ...
This vaccine is given as a series of shots, the first dose is given at birth, the second between 1 and 2 months, and the third, and possibly fourth, between 6 and 18 months. Some side effects of this vaccination include: soreness at injection site (1 in 4 children) fever of 99.9 degrees Fahrenheit or higher (1 in 15 children) brief fainting spell
[32] [33] Liraglutide was approved by the FDA in 2019, for treatment of children ten years or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000. [34] Novo Nordisk made deals with generic manufacturers to enter the United States market in 2024.